Carta al editor.n the INSIGHT Strategic Timing of Antiretroviral Treatment (START) study, Lundgren et al. (Aug. 27 issue)1 conclude that antiretroviral therapy should be recommended for every patient with human immunodeficiency virus (HIV) infection regardless of the CD4+ count.Peer reviewe
Copyright © 2014 Matthias Haering et al. This is an open access article distributed under the Creati...
transient cART starte infection undermine the l n ad nc universal treatment of HIV infection regardl...
International audienceBACKGROUND: The CD4 cell count at which combination antiretroviral therapy sho...
Copyright © 2014 Babatunde Olubajo et al. This is an open access article distributed under the Creat...
In this article, the scientific evidence and professional guidelines regarding the timing of antiret...
Decisions regarding whether to start combination antiretroviral therapy (cART) during primary infect...
Highly active antiretroviral therapy (HAART),the use of combinations of antiretroviral drugs that ca...
Data from randomized trials are lacking on the benefits and risks of initiating antiretroviral thera...
In Kevin De Cock and Wafaa El-Sadr's Comment1, they address the importance of early antiretroviral t...
Abstract: Universal HIV testing and immediate antiret-roviral therapy for infected individuals has b...
The article of record as published may be found at http://dx.doi.org/10.1136/ebmed-2016-110576In 201...
The question of when to start combination antiretroviral therapy for treatment-naïve patients has al...
To the Editor: In their Perspective article, De Cock and El-Sadr (March 7 issue)1 highlight the nee...
The question about when to start antiretroviral therapy in HIV-1-infected patients has been debated ...
To the Editor—The invited article by Wilkin and Gulick [1] excellently sum-marizes the existing data...
Copyright © 2014 Matthias Haering et al. This is an open access article distributed under the Creati...
transient cART starte infection undermine the l n ad nc universal treatment of HIV infection regardl...
International audienceBACKGROUND: The CD4 cell count at which combination antiretroviral therapy sho...
Copyright © 2014 Babatunde Olubajo et al. This is an open access article distributed under the Creat...
In this article, the scientific evidence and professional guidelines regarding the timing of antiret...
Decisions regarding whether to start combination antiretroviral therapy (cART) during primary infect...
Highly active antiretroviral therapy (HAART),the use of combinations of antiretroviral drugs that ca...
Data from randomized trials are lacking on the benefits and risks of initiating antiretroviral thera...
In Kevin De Cock and Wafaa El-Sadr's Comment1, they address the importance of early antiretroviral t...
Abstract: Universal HIV testing and immediate antiret-roviral therapy for infected individuals has b...
The article of record as published may be found at http://dx.doi.org/10.1136/ebmed-2016-110576In 201...
The question of when to start combination antiretroviral therapy for treatment-naïve patients has al...
To the Editor: In their Perspective article, De Cock and El-Sadr (March 7 issue)1 highlight the nee...
The question about when to start antiretroviral therapy in HIV-1-infected patients has been debated ...
To the Editor—The invited article by Wilkin and Gulick [1] excellently sum-marizes the existing data...
Copyright © 2014 Matthias Haering et al. This is an open access article distributed under the Creati...
transient cART starte infection undermine the l n ad nc universal treatment of HIV infection regardl...
International audienceBACKGROUND: The CD4 cell count at which combination antiretroviral therapy sho...